PRNewsWire
05 Nov 2026, 12:45 UTC · 5h ago
Impact · against what's priced in
Intensity Therapeutics sees a potential catalyst in strong preliminary pCR data (71% vs 42%) for its Phase 2 study and the resumption of Phase 3 enrollment. However, limited ATM utilization suggests ongoing financing risk for scaling these trials.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Preliminary data from 14 patients in the Phase 2 INVINCIBLE-4 study showed a 71% pathological complete response (pCR) in the INT230-6 cohort compared to 42% in the SOC cohort.
Newpress release dated Nov 05, 2026
So whatThe 29 percentage point pCR advantage provides a strong catalyst for the IDMB safety review scheduled for Q1 2027.
More positive than 99% of claims this week
Continue reading
5 related stories
The company reported a significant pCR advantage of 29 percentage points in the INVINCIBLE-4 study and resumed Phase 3 enrollment in INVINCIBLE-3, though it has only utilized $3.2 million of its ATM facility over nine months.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Intensity Therapeutics resumed new patient enrollment in the Phase 3 INVINCIBLE-3 study in the third quarter of 2026 after a pause since March 2025.
Newpress release dated Nov 05, 2026
More positive than 92% of claims this week
The company raised net proceeds of $1.5 million under its $60 million at-the-market facility during the third quarter of 2026.
Newpress release dated Nov 05, 2026
So whatWith only $3.2 million raised total over nine months, the company remains heavily reliant on the remaining $56.8 million ATM capacity for future trial scaling.
More negative than 71% of claims this week
The INVINCIBLE-4 study is currently targeting complete enrollment by the end of 2027.
Newpress release dated Nov 05, 2026
So whatThis establishes a multi-quarter timeline for data maturation, pushing final Phase 2 results into 2028.
More positive than 39% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company resumed patient enrollment in two clinical trials and reported strong preliminary pCR data for its INT230-6 therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
47m ago
−17.4%
Price is moving against the score
$2.89 vs $3.50 close before publication (Nov 4) · not market-adjusted
INTS chart →
